Incretin hormones and the satiation signal

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Incretin hormones and the satiation signal. / Holst, Jens Juul.

I: International journal of obesity (2005), Bind 37, Nr. 9, 09.2013, s. 1161-8.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Holst, JJ 2013, 'Incretin hormones and the satiation signal', International journal of obesity (2005), bind 37, nr. 9, s. 1161-8. https://doi.org/10.1038/ijo.2012.208

APA

Holst, J. J. (2013). Incretin hormones and the satiation signal. International journal of obesity (2005), 37(9), 1161-8. https://doi.org/10.1038/ijo.2012.208

Vancouver

Holst JJ. Incretin hormones and the satiation signal. International journal of obesity (2005). 2013 sep.;37(9):1161-8. https://doi.org/10.1038/ijo.2012.208

Author

Holst, Jens Juul. / Incretin hormones and the satiation signal. I: International journal of obesity (2005). 2013 ; Bind 37, Nr. 9. s. 1161-8.

Bibtex

@article{56a9e3bda2bb475e8e920cafa65d4a61,
title = "Incretin hormones and the satiation signal",
abstract = "Recent research has indicated that appetite-regulating hormones from the gut may have therapeutic potential. The incretin hormone, glucagon-like peptide-1 (GLP-1), appears to be involved in both peripheral and central pathways mediating satiation. Several studies have also indicated that GLP-1 levels and responses to meals may be altered in obese subjects. Clinical trial results have shown further that two GLP-1 receptor agonists (GLP-1 RAs), exenatide and liraglutide, which are approved for the treatment of hyperglycemia in patients with type 2 diabetes, also produce weight loss in overweight subjects without diabetes. Thus, GLP-1 RAs may provide a new option for pharmacological treatment of obesity.",
keywords = "Animals, Eating, Gastric Inhibitory Polypeptide, Glucagon-Like Peptide 1, Humans, Hyperglycemia, Hypoglycemic Agents, Incretins, Obesity, Peptides, Receptors, Glucagon, Satiation, Signal Transduction, Venoms, Weight Loss",
author = "Holst, {Jens Juul}",
year = "2013",
month = sep,
doi = "10.1038/ijo.2012.208",
language = "English",
volume = "37",
pages = "1161--8",
journal = "International Journal of Obesity",
issn = "0307-0565",
publisher = "nature publishing group",
number = "9",

}

RIS

TY - JOUR

T1 - Incretin hormones and the satiation signal

AU - Holst, Jens Juul

PY - 2013/9

Y1 - 2013/9

N2 - Recent research has indicated that appetite-regulating hormones from the gut may have therapeutic potential. The incretin hormone, glucagon-like peptide-1 (GLP-1), appears to be involved in both peripheral and central pathways mediating satiation. Several studies have also indicated that GLP-1 levels and responses to meals may be altered in obese subjects. Clinical trial results have shown further that two GLP-1 receptor agonists (GLP-1 RAs), exenatide and liraglutide, which are approved for the treatment of hyperglycemia in patients with type 2 diabetes, also produce weight loss in overweight subjects without diabetes. Thus, GLP-1 RAs may provide a new option for pharmacological treatment of obesity.

AB - Recent research has indicated that appetite-regulating hormones from the gut may have therapeutic potential. The incretin hormone, glucagon-like peptide-1 (GLP-1), appears to be involved in both peripheral and central pathways mediating satiation. Several studies have also indicated that GLP-1 levels and responses to meals may be altered in obese subjects. Clinical trial results have shown further that two GLP-1 receptor agonists (GLP-1 RAs), exenatide and liraglutide, which are approved for the treatment of hyperglycemia in patients with type 2 diabetes, also produce weight loss in overweight subjects without diabetes. Thus, GLP-1 RAs may provide a new option for pharmacological treatment of obesity.

KW - Animals

KW - Eating

KW - Gastric Inhibitory Polypeptide

KW - Glucagon-Like Peptide 1

KW - Humans

KW - Hyperglycemia

KW - Hypoglycemic Agents

KW - Incretins

KW - Obesity

KW - Peptides

KW - Receptors, Glucagon

KW - Satiation

KW - Signal Transduction

KW - Venoms

KW - Weight Loss

U2 - 10.1038/ijo.2012.208

DO - 10.1038/ijo.2012.208

M3 - Journal article

C2 - 23295502

VL - 37

SP - 1161

EP - 1168

JO - International Journal of Obesity

JF - International Journal of Obesity

SN - 0307-0565

IS - 9

ER -

ID: 117854797